EGFR and glioblastoma: Taken together, our report of the strong sensitivity of EGFR ECD variants to dacomitinib, as well as observed clinical responses of EGFR G598V, prompt additional consideration of dacomitinib for glioblastomas with EGFR ECD mutations.